4'-(3-furyl)biphenyl-3-ol | 1233720-63-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4'-(3-furyl)biphenyl-3-ol
• 英文别名: 3-[4-(Furan-3-yl)phenyl]phenol
• CAS: 1233720-63-2
• 化学式: C₁₆H₁₂O₂
• 分子量: 236.27
• InChiKey: WZSNLNMGRLTJIP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  33.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-呋喃硼酸 、 4-溴-1,1'-联苯酚 在 四(三苯基膦)钯 、 caesium carbonate 作用下， 以 乙二醇二甲醚 、 乙醇 、 水 为溶剂， 150.0 ℃ 、1.5 MPa 条件下， 反应 0.25h， 以3%的产率得到4'-(3-furyl)biphenyl-3-ol
  参考文献：
  名称：

  Novel estrone mimetics with high 17β-HSD1 inhibitory activity

  摘要：

  17 beta-Hydroxysteroid dehydrogenase type 1 (17 beta-HSD1) catalyzes the reduction of estrone into estradiol, which is the most potent estrogen in humans. Lowering intracellular estradiol concentration by inhibition of this enzyme is a promising new option for the treatment of estrogen-dependent diseases like breast cancer and endometriosis. Combination of ligand- and structure-based design resulted in heterocyclic substituted biphenylols and their aza-analogs as new 17 beta-HSD1 inhibitors. The design was based on mimicking estrone, especially focusing on the imitation of the D-ring keto group with (substituted) heterocycles. Molecular docking provided insights into plausible protein-ligand interactions for this class of compounds. The most promising compound 12 showed an inhibitory activity in the high nanomolar range and very low affinity for the estrogen receptors alpha and beta. Thus, compound 12 is a novel tool for the elucidation of the pharmacological relevance of 17 beta-HSD1 and might be a lead for the treatment of estrogen-dependent diseases. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.03.065

文献信息

• Novel estrone mimetics with high 17β-HSD1 inhibitory activity
  作者：Alexander Oster、Tobias Klein、Ruth Werth、Patricia Kruchten、Emmanuel Bey、Matthias Negri、Sandrine Marchais-Oberwinkler、Martin Frotscher、Rolf W. Hartmann

  DOI：10.1016/j.bmc.2010.03.065

  日期：2010.5

  17 beta-Hydroxysteroid dehydrogenase type 1 (17 beta-HSD1) catalyzes the reduction of estrone into estradiol, which is the most potent estrogen in humans. Lowering intracellular estradiol concentration by inhibition of this enzyme is a promising new option for the treatment of estrogen-dependent diseases like breast cancer and endometriosis. Combination of ligand- and structure-based design resulted in heterocyclic substituted biphenylols and their aza-analogs as new 17 beta-HSD1 inhibitors. The design was based on mimicking estrone, especially focusing on the imitation of the D-ring keto group with (substituted) heterocycles. Molecular docking provided insights into plausible protein-ligand interactions for this class of compounds. The most promising compound 12 showed an inhibitory activity in the high nanomolar range and very low affinity for the estrogen receptors alpha and beta. Thus, compound 12 is a novel tool for the elucidation of the pharmacological relevance of 17 beta-HSD1 and might be a lead for the treatment of estrogen-dependent diseases. (C) 2010 Elsevier Ltd. All rights reserved.